KPV for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

KPV for Health & Longevity

Created on 08/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

KPV is a three-amino-acid fragment of a natural human hormone, chosen to keep its ability to switch off inflammation without darkening skin. The laboratory and animal case is coherent, strongest in the gut. In more than forty years it has never been tested in a controlled human study. Most sold product is made outside pharmaceutical quality standards. (Full Review)

Protocol

Standard practice protocol
200–500 µg subcutaneously once daily
Gut-directed: 500 µg–1 mg orally once or twice daily, enteric-coated; topical at 0.5–1%. Used in 4–8 week blocks. Figures from clinician-educator networks and compounding pharmacies, not trials.
Best time of day
30–60 min before food
Or 2 hours after, for oral use; dietary peptides compete for the same transporter. No chronobiological rationale for subcutaneous use; topical typically at night.
Single versus split dosing
Split dosing
More defensible given rapid peptidase degradation; splitting the same total dose is lower-risk than raising it, since the original dose-response was bell-shaped.
Time to effect
Gut-related change
1–2 weeks
From practitioner protocols; consistent with animal colitis models but not evidence. No human data define this.
Skin-related change
3–4 weeks
From practitioner protocols only. Unassisted topical KPV penetrates skin below the detection limit.
Assessment window
4–8 weeks
4 weeks for a gut endpoint, 8 weeks for anything else; beyond that, continuing without a measured change is continuing on hope.

Benefits

Contraindications
  • Pregnancy and lactation
  • Active malignancy, or malignancy in remission for less than 5 years
  • Transplant recipients on maintenance immunosuppression; primary or acquired immunodeficiency (CD4 below 200 cells/µL)
  • Active untreated infection, including latent tuberculosis
  • Baseline neutrophils below 1.5 × 10⁹/L or lymphocytes below 1.0 × 10⁹/L
  • Children and adolescents under 18
  • No access to a product with independent identity, purity and endotoxin testing
  • Competitive sport
    •
Key Interactions
  • PepT1 substrate competition: β-lactams (cephalexin, amoxicillin), valacyclovir, ACE inhibitors (enalapril, captopril)
  • Systemic immunosuppressants (prednisone, tacrolimus, ciclosporin, methotrexate)
  • Biologic anti-inflammatory therapies (infliximab, adalimumab, ustekinumab, tofacitinib)
  • Non-steroidal anti-inflammatory drugs, or NSAIDs (ibuprofen, naproxen, aspirin, diclofenac)
  • Acid suppression: proton pump inhibitors (omeprazole), H2 blockers (famotidine)
  • Supplements with additive anti-inflammatory effect (curcumin, omega-3, boswellia, resveratrol)
  • Supplements affecting the same target (high-dose zinc, berberine, glutamine, zinc carnosine)
  • Other peptide interventions (BPC-157, TB-500, thymosin alpha-1, rapamycin)
  • Live attenuated vaccines (yellow fever, measles-mumps-rubella, influenza)
    •

Risk & Side Effects

  • High: Absence of any human safety data; unregulated supply and product quality risk
  • Medium: Impairment of host defence
    •
  • Low: Injection-site and local reactions; hypersensitivity and histamine-mediated reactions; gastrointestinal symptoms with oral or rectal use; masking of inflammatory signals
  • Speculative: Melanocortin-axis off-target effects; consequences of chronic inflammatory suppression for tumour surveillance; altered gut microbiome

Monitoring

Marker Target Why
hs-CRP < 0.5 mg/L (men), < 1.0 mg/L (women) Primary readout of the inflammation KPV targets
Fecal calprotectin < 50 µg/g Most sensitive marker of gut mucosal inflammation
IL-6 < 1.5 pg/mL Upstream driver of hs-CRP; changes earlier
Complete blood count with differential Total white cells 4.5–6.5 × 10⁹/L; absolute neutrophils 1.8–4.0 × 10⁹/L; lymphocytes 1.5–3.0 × 10⁹/L Only detection route for immune suppression
Comprehensive metabolic panel ALT < 25 U/L (men), < 20 U/L (women); eGFR ≥ 90 mL/min/1.73 m² Hepatic and renal signals; no published toxicology
Ferritin 50–150 ng/mL (men), 30–100 ng/mL (women) Slower-moving inflammatory cross-check on hs-CRP
Fasting insulin < 5 µIU/mL Tracks with inflammation; worsening flags a confounder

Cadence: Baseline before the first dose, ideally on two occasions a week apart. Full panel at 8 weeks, at the end of the first off-period, then every 3–6 months. Blood count and liver panel at 4 weeks if the dose is escalated or febrile illness occurs.

Qualitative Assessment

  • Gastrointestinal symptom burden — stool form, bloating, urgency and discomfort, scored daily rather than recalled
  • Joint stiffness and morning function — duration of morning stiffness in minutes, more reliable than a pain score
  • Skin appearance and reactivity — redness, flare frequency and barrier symptoms, with fixed-lighting photographs
  • Energy and post-exertional recovery — time to feel recovered after a hard session, which tracks inflammatory state
  • Cognitive clarity and mood — commonly claimed for peptides and most likely to move on expectation alone
  • Sleep quality and continuity — a confounder check; a change here alters nearly every other marker
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.